首页 > 最新文献

Experimental oncology最新文献

英文 中文
PROSTATE CANCER DIAGNOSTICS MODELING USING THE INFRARED IMAGING METHOD. 利用红外成像方法建立前列腺癌诊断模型。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.268
B Partsvania, T Sulaberidze, A Khuskivadze, S Abazadze

Background: Imaging plays an important role in the identification of prostate cancer (PCa). However, a shortcoming of the current imaging techniques is their inability to detect PCa at an early stage of development when tumor volume is small. This led us to explore new and improved imaging methods. The phenomenon that infrared (IR) light penetrates biological tissues caused our efforts to utilize IR rays for PCa visualization. The aim of this study was to conduct model experiments to demonstrate how IR light could be used in the future to detect PCa in vivo.

Materials and methods: Experiments were carried out on prostates obtained after radical prostatectomy. The study was approved by the ethical commission of the Georgia-Israel Joint Clinic "Gidmedi". We developed a device that uses IR light to illuminate a prostate from the inside. In order to get IR images of the prostate, we developed a device with an IR-sensitive charge-coupled device (CCD) camera. The model experiments showed that the intensity of IR light passing through noncancerous and malignant prostate tissues is significantly different allowing their distinguishment. The visualization device can detect PCa lesions as small as several millimeters.

Conclusion: These results suggest that our device could be useful for the detection of small PCa lesions.

背景:影像学在前列腺癌(PCa)的鉴别中起着重要的作用。然而,当前成像技术的一个缺点是无法在肿瘤体积很小的早期发现前列腺癌。这促使我们探索新的和改进的成像方法。红外(IR)光穿透生物组织的现象促使我们努力利用红外线进行PCa可视化。本研究的目的是进行模型实验,以证明未来如何使用红外光在体内检测PCa。材料与方法:对根治性前列腺切除术后获得的前列腺进行实验。这项研究得到了格鲁吉亚-以色列联合诊所“Gidmedi”伦理委员会的批准。我们开发了一种利用红外线从内部照射前列腺的装置。为了获得前列腺的红外图像,我们研制了一种带有红外敏感电荷耦合器件(CCD)相机的装置。模型实验表明,通过非癌性前列腺组织和恶性前列腺组织的红外光强度有显著差异,可以区分它们。可视化设备可以检测到小到几毫米的前列腺癌病变。结论:本装置可用于前列腺癌小病变的检测。
{"title":"PROSTATE CANCER DIAGNOSTICS MODELING USING THE INFRARED IMAGING METHOD.","authors":"B Partsvania, T Sulaberidze, A Khuskivadze, S Abazadze","doi":"10.15407/exp-oncology.2024.03.268","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.268","url":null,"abstract":"<p><strong>Background: </strong>Imaging plays an important role in the identification of prostate cancer (PCa). However, a shortcoming of the current imaging techniques is their inability to detect PCa at an early stage of development when tumor volume is small. This led us to explore new and improved imaging methods. The phenomenon that infrared (IR) light penetrates biological tissues caused our efforts to utilize IR rays for PCa visualization. The aim of this study was to conduct model experiments to demonstrate how IR light could be used in the future to detect PCa in vivo.</p><p><strong>Materials and methods: </strong>Experiments were carried out on prostates obtained after radical prostatectomy. The study was approved by the ethical commission of the Georgia-Israel Joint Clinic \"Gidmedi\". We developed a device that uses IR light to illuminate a prostate from the inside. In order to get IR images of the prostate, we developed a device with an IR-sensitive charge-coupled device (CCD) camera. The model experiments showed that the intensity of IR light passing through noncancerous and malignant prostate tissues is significantly different allowing their distinguishment. The visualization device can detect PCa lesions as small as several millimeters.</p><p><strong>Conclusion: </strong>These results suggest that our device could be useful for the detection of small PCa lesions.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"268-272"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SIGNIFICANCE OF miRNA-185-5P AND miRNA-424-5P AS PROGNOSTIC MARKERS IN PROGRESSION OF EARLY-STAGE ENDOMETRIAL CANCER. miRNA-185-5P和miRNA-424-5P在早期晚期肿瘤进展过程中作为预后标志物的意义。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.244
N P Iurchenko, N M Glushchenko, S V Nespryadko, L G Buchynska

Aim: To compare the expression of miRNA-185-5p and miRNA-424-5p in tumor cells and peripheral blood serum (PBS) of patients with endometrioid carcinoma of the endometrium (ECE) and to evaluate the significance of these biomarkers in cancer progression.

Materials and methods: The study was conducted on the samples of peripheral blood serum (PBS) and tumor tissue of 58 patients with stage I ECE using clinical and morphological methods and real-time polymerase chain reaction.

Results: A significant increase in the levels of circulating and tumor-associated miRNA-424-5p was established in ECE patients with a history of recurrences compared to patients without recurrences. To the contrary, the expression level of miRNA-185-5p increased in the PBS and decreased in the tumor tissue of ECE patients with recurrences compared to the patients without recurrence. In addition, we revealed that the expression levels of the studied miRNAs were associated with the differentiation grade and degree of tumor invasion. We established that miRNA-424-5p levels in PBS could serve as the most significant indicator for predicting the occurrence of recurrence in patients with ECE (AUC = 0.991; Sp 94.0%; Se 99.9%).

Conclusions: The expression features of miRNA-185-5p and miRNA-424-5p in the PBS and tumor tissue of patients with ECE are associated with the aggressiveness of cancer course and the risk of recurrence.

目的:比较miRNA-185-5p和miRNA-424-5p在子宫内膜子宫内膜样癌(ECE)患者肿瘤细胞和外周血血清(PBS)中的表达,并评价这些生物标志物在肿瘤进展中的意义。材料与方法:采用临床和形态学方法及实时聚合酶链反应对58例I期ECE患者外周血血清(PBS)和肿瘤组织标本进行研究。结果:与无复发病史的ECE患者相比,有复发病史的ECE患者循环和肿瘤相关miRNA-424-5p水平显著升高。相反,与未复发患者相比,复发ECE患者肿瘤组织中miRNA-185-5p的表达水平在PBS中升高而在肿瘤组织中降低。此外,我们发现所研究的mirna的表达水平与肿瘤的分化等级和侵袭程度有关。我们发现PBS中miRNA-424-5p水平可以作为预测ECE患者复发的最显著指标(AUC = 0.991;Sp 94.0%;Se 99.9%)。结论:miRNA-185-5p和miRNA-424-5p在ECE患者PBS和肿瘤组织中的表达特征与病程的侵袭性和复发风险相关。
{"title":"SIGNIFICANCE OF miRNA-185-5P AND miRNA-424-5P AS PROGNOSTIC MARKERS IN PROGRESSION OF EARLY-STAGE ENDOMETRIAL CANCER.","authors":"N P Iurchenko, N M Glushchenko, S V Nespryadko, L G Buchynska","doi":"10.15407/exp-oncology.2024.03.244","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.244","url":null,"abstract":"<p><strong>Aim: </strong>To compare the expression of miRNA-185-5p and miRNA-424-5p in tumor cells and peripheral blood serum (PBS) of patients with endometrioid carcinoma of the endometrium (ECE) and to evaluate the significance of these biomarkers in cancer progression.</p><p><strong>Materials and methods: </strong>The study was conducted on the samples of peripheral blood serum (PBS) and tumor tissue of 58 patients with stage I ECE using clinical and morphological methods and real-time polymerase chain reaction.</p><p><strong>Results: </strong>A significant increase in the levels of circulating and tumor-associated miRNA-424-5p was established in ECE patients with a history of recurrences compared to patients without recurrences. To the contrary, the expression level of miRNA-185-5p increased in the PBS and decreased in the tumor tissue of ECE patients with recurrences compared to the patients without recurrence. In addition, we revealed that the expression levels of the studied miRNAs were associated with the differentiation grade and degree of tumor invasion. We established that miRNA-424-5p levels in PBS could serve as the most significant indicator for predicting the occurrence of recurrence in patients with ECE (AUC = 0.991; Sp 94.0%; Se 99.9%).</p><p><strong>Conclusions: </strong>The expression features of miRNA-185-5p and miRNA-424-5p in the PBS and tumor tissue of patients with ECE are associated with the aggressiveness of cancer course and the risk of recurrence.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"244-252"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDENTIFICATION OF CLINICALLY RELEVANT GENE VARIANTS IN COLON ADENOCARCINOMA SAMPLES OF UKRAINIAN PATIENTS USING A COMPREHENSIVE CANCER PANEL: A PILOT STUDY. 使用综合癌症小组鉴定乌克兰患者结肠腺癌样本中临床相关基因变异:一项试点研究。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.221
G Gerashchenko, R Gulkovskyi, N Melnichuk, N Hryshchenko, T Marchyshak, O Mankovska, A Bezverkhiy, I Kotuza, L Rosha, A Kotuza, Z Tkachuk, V Kashuba, M Tukalo

The study aimed to identify the clinically relevant gene variants in colon adenocarcinoma samples of Ukrainian patients using the NGS Comprehensive Cancer Panel (CCP) to implement them conveniently in clinical practice.

Methods: We have studied 20 samples of Ukrainian patients with colorectal adenocarcinomas of various differentiation grades. To identify the clinically relevant gene variants, the CCP data were filtered using the Franklin by Genoox database.

Results: A total of 79 clinically relevant gene variant alterations (SNVs, INDELs) were found in 28 of 409 genes. The largest number of mutations was found in 3 genes, APC, TP53, and KRAS (16, 14, and 8, accordingly). We revealed 4 variants in PTEN and SMAD4, 3 variants in CHEK2, ERBB2, and PIK3CA genes, and 2 variants in AKT1, ATM, DST, IDH1, and TCF12. Mutations for 7 genes, KRAS, TP53, CHEK2, PTEN, AKT1, APC, and SMAD4, were found in more than 1 tumor tissue sample. Tier 1-2 gene variants rate was about 50% of all genetic variants. The therapeutic significance was found in more than 55% of mutations. Additionally, 11 novel genetic mutations in 9 genes have been identified, including G6PD, APC, DST, SINE1, SMAD2, and FLCN.

Conclusions: These data suggest a high level of clinical relevance of the NGS CCP approach. Further confirmation on a larger number of samples and using a deeper analysis by other approaches is required.

本研究旨在利用NGS Comprehensive Cancer Panel (CCP)识别乌克兰患者结肠腺癌样本中临床相关的基因变异,以便在临床实践中方便实施。方法:我们对乌克兰20例不同分化级别的结直肠癌患者进行了研究。为了确定临床相关的基因变异,CCP数据使用Franklin by Genoox数据库进行过滤。结果:409个基因中28个共发现79个临床相关基因变异(SNVs, INDELs)。APC、TP53和KRAS 3个基因的突变数量最多(分别为16、14和8)。我们在PTEN和SMAD4基因中发现了4个变异,CHEK2、ERBB2和PIK3CA基因中发现了3个变异,AKT1、ATM、DST、IDH1和TCF12基因中发现了2个变异。KRAS、TP53、CHEK2、PTEN、AKT1、APC和SMAD4 7个基因在1个以上的肿瘤组织样本中发现突变。1-2级基因变异率约占所有基因变异的50%。在超过55%的突变中发现了治疗意义。此外,还发现了G6PD、APC、DST、SINE1、SMAD2和FLCN等9个基因的11个新基因突变。结论:这些数据表明NGS CCP入路具有很高的临床相关性。需要对更多的样本进行进一步确认,并采用其他方法进行更深入的分析。
{"title":"IDENTIFICATION OF CLINICALLY RELEVANT GENE VARIANTS IN COLON ADENOCARCINOMA SAMPLES OF UKRAINIAN PATIENTS USING A COMPREHENSIVE CANCER PANEL: A PILOT STUDY.","authors":"G Gerashchenko, R Gulkovskyi, N Melnichuk, N Hryshchenko, T Marchyshak, O Mankovska, A Bezverkhiy, I Kotuza, L Rosha, A Kotuza, Z Tkachuk, V Kashuba, M Tukalo","doi":"10.15407/exp-oncology.2024.03.221","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.221","url":null,"abstract":"<p><p>The study aimed to identify the clinically relevant gene variants in colon adenocarcinoma samples of Ukrainian patients using the NGS Comprehensive Cancer Panel (CCP) to implement them conveniently in clinical practice.</p><p><strong>Methods: </strong>We have studied 20 samples of Ukrainian patients with colorectal adenocarcinomas of various differentiation grades. To identify the clinically relevant gene variants, the CCP data were filtered using the Franklin by Genoox database.</p><p><strong>Results: </strong>A total of 79 clinically relevant gene variant alterations (SNVs, INDELs) were found in 28 of 409 genes. The largest number of mutations was found in 3 genes, APC, TP53, and KRAS (16, 14, and 8, accordingly). We revealed 4 variants in PTEN and SMAD4, 3 variants in CHEK2, ERBB2, and PIK3CA genes, and 2 variants in AKT1, ATM, DST, IDH1, and TCF12. Mutations for 7 genes, KRAS, TP53, CHEK2, PTEN, AKT1, APC, and SMAD4, were found in more than 1 tumor tissue sample. Tier 1-2 gene variants rate was about 50% of all genetic variants. The therapeutic significance was found in more than 55% of mutations. Additionally, 11 novel genetic mutations in 9 genes have been identified, including G6PD, APC, DST, SINE1, SMAD2, and FLCN.</p><p><strong>Conclusions: </strong>These data suggest a high level of clinical relevance of the NGS CCP approach. Further confirmation on a larger number of samples and using a deeper analysis by other approaches is required.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"221-227"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA. 适形放疗联合放射调节剂对头颈部鳞状细胞癌患者血清中 VEGF、COX-2 和 PGE-2 含量的影响。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.253
N Mitryayeva, L Grebinyk, S Artiukh, N Bilozor, V Starenkiy

Background: The development of new approaches to modeling tumor radiosensitivity in patients with head and neck squamous cell carcinoma (HNSCC) is an important problem for overcoming tumor radioresistance. New agents for radiomodification are inhibitors of the enzyme cyclooxygenase-2 (COX-2). The study of markers of radioresistance in cancer patients undergoing radiotherapy (RT) in combination with COX-2 inhibitors and chemotherapy may contribute to the effectiveness of RT.

Aim: To determine the effect of conformal RT in combination with radiomodifiers (celecoxib, cisplatin, or their combination) on the content of vascular endothelial growth factor (VEGF), COX-2, and prostaglandin E-2 (PGE-2) in the serum of patients with HNSCC.

Materials and methods: 47 patients with HNSCC were divided into 4 groups: RT in combination with celecoxib and cisplatin, RT with cisplatin, RT with celecoxib, and RT. Patients received radiation treatment on a Clinac 600C linear accelerator. The levels of VEGF, COX-2, and PGE-2 in the serum were determined by enzyme immunoassay.

Results: Blocking COX-2 in patients with HNSCC leads to a decrease in VEGF levels. The largest decrease in VEGF levels was observed in a group treated by RT in combination with celecoxib and cisplatin, indicating a more effective antiangiogenic effect. The changes in the levels of VEGF, COX-2, and PGE-2, which are most pronounced under the combined effect of RT and both radiomodifiers, coincided with an objective response to radiation treatment.

Conclusions: The data obtained indicate the effect of radiomodification on the suppression of angiogenesis, which is most pronounced under the combined effect of RT and both radiomodifiers. The decrease in the levels of PGE- 2, COX-2, and VEGF coincides with the clinical efficacy of radiotherapy according to RECIST 1.1 criteria.

背景:建立头颈部鳞状细胞癌(HNSCC)患者肿瘤放射敏感性模型的新方法是克服肿瘤放射耐药的重要问题。新的放射性修饰剂是环氧化酶-2 (COX-2)的抑制剂。目的:探讨适形放疗联合放射调节剂(塞来昔布、顺铂或其联合用药)对HNSCC患者血清血管内皮生长因子(VEGF)、COX-2、前列腺素E-2含量的影响。材料与方法:将47例HNSCC患者分为4组:塞来昔布联合顺铂放疗组、塞来昔布联合顺铂放疗组、塞来昔布放疗组和放疗组。患者在Clinac 600C直线加速器上进行放疗。采用酶免疫法检测血清中VEGF、COX-2、PGE-2水平。结果:在HNSCC患者中阻断COX-2可导致VEGF水平降低。在RT联合塞来昔布和顺铂治疗组中,VEGF水平下降幅度最大,表明其抗血管生成作用更有效。VEGF、COX-2和PGE-2水平的变化,在RT和两种放射调节剂联合作用下最为明显,与放射治疗的客观反应相吻合。结论:放疗对血管生成的抑制作用在放疗和两种放疗联合作用下最为明显。PGE- 2、COX-2、VEGF水平的下降与RECIST 1.1标准放射治疗的临床疗效一致。
{"title":"INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA.","authors":"N Mitryayeva, L Grebinyk, S Artiukh, N Bilozor, V Starenkiy","doi":"10.15407/exp-oncology.2024.03.253","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.253","url":null,"abstract":"<p><strong>Background: </strong>The development of new approaches to modeling tumor radiosensitivity in patients with head and neck squamous cell carcinoma (HNSCC) is an important problem for overcoming tumor radioresistance. New agents for radiomodification are inhibitors of the enzyme cyclooxygenase-2 (COX-2). The study of markers of radioresistance in cancer patients undergoing radiotherapy (RT) in combination with COX-2 inhibitors and chemotherapy may contribute to the effectiveness of RT.</p><p><strong>Aim: </strong>To determine the effect of conformal RT in combination with radiomodifiers (celecoxib, cisplatin, or their combination) on the content of vascular endothelial growth factor (VEGF), COX-2, and prostaglandin E-2 (PGE-2) in the serum of patients with HNSCC.</p><p><strong>Materials and methods: </strong>47 patients with HNSCC were divided into 4 groups: RT in combination with celecoxib and cisplatin, RT with cisplatin, RT with celecoxib, and RT. Patients received radiation treatment on a Clinac 600C linear accelerator. The levels of VEGF, COX-2, and PGE-2 in the serum were determined by enzyme immunoassay.</p><p><strong>Results: </strong>Blocking COX-2 in patients with HNSCC leads to a decrease in VEGF levels. The largest decrease in VEGF levels was observed in a group treated by RT in combination with celecoxib and cisplatin, indicating a more effective antiangiogenic effect. The changes in the levels of VEGF, COX-2, and PGE-2, which are most pronounced under the combined effect of RT and both radiomodifiers, coincided with an objective response to radiation treatment.</p><p><strong>Conclusions: </strong>The data obtained indicate the effect of radiomodification on the suppression of angiogenesis, which is most pronounced under the combined effect of RT and both radiomodifiers. The decrease in the levels of PGE- 2, COX-2, and VEGF coincides with the clinical efficacy of radiotherapy according to RECIST 1.1 criteria.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"253-259"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ROLE OF RIBONUCLEASES IN THE REGULATION OF IMMUNE RESPONSE. 核糖核酸酶在免疫反应调控中的作用。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.192
V Shlyakhovenko, O Samoylenko, A Verbinenko, I Ganusevich

Ribonucleases (RNases) perform many different functions in living systems. They are responsible for the formation and processing of various ribonucleic acids (RNAs), including the messenger RNA and all types of microRNAs, and determine the duration of the existence of different RNAs in the cell and extracellular environment. RNases are ubiquitously expressed in many tissue types. This short review discusses the major types and main functions of RNases, their homeostatic functions, influence of transcription, immunomodulation, and the role of extracellular RNases in the immune defense mechanisms.

核糖核酸酶(RNases)在生命系统中发挥着多种不同的功能。它们负责形成和处理各种核糖核酸(RNA),包括信使 RNA 和所有类型的 microRNA,并决定不同 RNA 在细胞和细胞外环境中的存在时间。RNase 在许多组织类型中普遍表达。这篇简短的综述将讨论 RNases 的主要类型和主要功能、它们的平衡功能、对转录的影响、免疫调节以及细胞外 RNases 在免疫防御机制中的作用。
{"title":"ROLE OF RIBONUCLEASES IN THE REGULATION OF IMMUNE RESPONSE.","authors":"V Shlyakhovenko, O Samoylenko, A Verbinenko, I Ganusevich","doi":"10.15407/exp-oncology.2024.03.192","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.192","url":null,"abstract":"<p><p>Ribonucleases (RNases) perform many different functions in living systems. They are responsible for the formation and processing of various ribonucleic acids (RNAs), including the messenger RNA and all types of microRNAs, and determine the duration of the existence of different RNAs in the cell and extracellular environment. RNases are ubiquitously expressed in many tissue types. This short review discusses the major types and main functions of RNases, their homeostatic functions, influence of transcription, immunomodulation, and the role of extracellular RNases in the immune defense mechanisms.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"192-201"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AGGRESSIVE RHABDOID TUMOR IN THE RIGHT LUNG: A CASE REPORT. 右肺侵袭性横纹肌样瘤1例。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.273
O Dyadyk, C Shatrova, V Ilchenko, L Rosha, V Zaritska, I Irkin, Yu Beketova, P Snisarevskyi

Rhabdoid tumor is a rare and aggressive neoplasm that usually occurs in children and is often localized in the central nervous system and kidneys, but can be found in many other sites. In our case report, we describe a tumor that was found on computed tomography in the thoracic region of a 62-year-old male and was successfully surgically resected. The images and descriptions of our findings and the results of the additional immunohistochemical studies allow us to make the final diagnosis.

横纹肌样肿瘤是一种罕见的侵袭性肿瘤,通常发生在儿童,通常局限于中枢神经系统和肾脏,但也可以在许多其他部位发现。在我们的病例报告中,我们描述了一个62岁男性胸部区域的计算机断层扫描发现的肿瘤,并成功手术切除。我们发现的图像和描述以及额外的免疫组织化学研究结果使我们能够做出最终诊断。
{"title":"AGGRESSIVE RHABDOID TUMOR IN THE RIGHT LUNG: A CASE REPORT.","authors":"O Dyadyk, C Shatrova, V Ilchenko, L Rosha, V Zaritska, I Irkin, Yu Beketova, P Snisarevskyi","doi":"10.15407/exp-oncology.2024.03.273","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.273","url":null,"abstract":"<p><p>Rhabdoid tumor is a rare and aggressive neoplasm that usually occurs in children and is often localized in the central nervous system and kidneys, but can be found in many other sites. In our case report, we describe a tumor that was found on computed tomography in the thoracic region of a 62-year-old male and was successfully surgically resected. The images and descriptions of our findings and the results of the additional immunohistochemical studies allow us to make the final diagnosis.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"273-277"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EVOLUTION OF METFORMIN IN BREAST CANCER THERAPY IN LAST TWO DECADES: A REVIEW. 近二十年来二甲双胍在乳腺癌治疗中的进展综述。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.185
R Sarathi, S Sarumathy, V M Durai Mavalavan

Among women, breast cancer is one of the most prevalent cancers. The disease has a complex etiology, with multiple biological pathways contributing to its development. As insulin signaling has mitogenic effects, glucose is a necessary cellular metabolic substrate, and the growth and metastasis of breast cancer are closely related to cellular glucose metabolism. Anti-diabetic medications have drawn increased attention as a potential treatment for breast cancer. Metformin lowers cancer incidence and death rates in patients with type 2 diabetes, according to epidemiologic studies. Preclinical studies conducted in vivo and in vitro offer fascinating new insights into the cellular mechanisms underlying metformin oncostatic action. We present an overview of the mechanisms of anticancer effects of metformin and discuss its potential function as an adjuvant in the treatment of breast cancer.

在女性中,乳腺癌是最常见的癌症之一。该疾病具有复杂的病因学,多种生物学途径有助于其发展。由于胰岛素信号具有促有丝分裂作用,葡萄糖是细胞必需的代谢底物,乳腺癌的生长和转移与细胞葡萄糖代谢密切相关。抗糖尿病药物作为一种潜在的乳腺癌治疗方法已经引起了越来越多的关注。根据流行病学研究,二甲双胍可以降低2型糖尿病患者的癌症发病率和死亡率。在体内和体外进行的临床前研究为二甲双胍肿瘤稳态作用的细胞机制提供了令人着迷的新见解。我们概述了二甲双胍的抗癌作用机制,并讨论了其作为辅助治疗乳腺癌的潜在功能。
{"title":"EVOLUTION OF METFORMIN IN BREAST CANCER THERAPY IN LAST TWO DECADES: A REVIEW.","authors":"R Sarathi, S Sarumathy, V M Durai Mavalavan","doi":"10.15407/exp-oncology.2024.03.185","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.185","url":null,"abstract":"<p><p>Among women, breast cancer is one of the most prevalent cancers. The disease has a complex etiology, with multiple biological pathways contributing to its development. As insulin signaling has mitogenic effects, glucose is a necessary cellular metabolic substrate, and the growth and metastasis of breast cancer are closely related to cellular glucose metabolism. Anti-diabetic medications have drawn increased attention as a potential treatment for breast cancer. Metformin lowers cancer incidence and death rates in patients with type 2 diabetes, according to epidemiologic studies. Preclinical studies conducted in vivo and in vitro offer fascinating new insights into the cellular mechanisms underlying metformin oncostatic action. We present an overview of the mechanisms of anticancer effects of metformin and discuss its potential function as an adjuvant in the treatment of breast cancer.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"185-191"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. 影响血液系统恶性肿瘤患者COVID-19预后的因素
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.260
A M Rudzite, D Auzina, S Lejniece

Background: Patients with hematological malignancies (HM) are considered to have a high risk of developing severe and life-threatening infections including COVID-19 because of immune deficiency and immunosuppressive treatments. Although the COVID pandemic spread worldwide, morbidity and mortality data varied from country to country. A more accurate identification of risk factors would allow the improvement of the clinical management of HM patients.

Aim: This study aimed to determine real-life data - the mortality rate, clinical outcomes, and risk factors affecting mortality in patients with HM and COVID-19 at the Riga East University Hospital (REUH) in Latvia.

Materials and methods: In this retrospective non-interventional cohort study, we included adult patients treated in REUH with ongoing HM and laboratory- confirmed COVID-19 observed between December 1st, 2020, and March 31st, 2023. All data were analyzed using descriptive statistics, binary logistic regression, univariable Cox regression model, and other methods.

Results: We registered 156 patients with 11 different HMs. Multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia were the most common HM. COVID-19 mortality rate was 19.9% (31/156). Factors increasing the risk of death included the severity of COVID-19 (p < 0.001), the accession of bacterial infection (p < 0.001), longer hospital stay (p = 0.037), absolute neutrophil count (ANC) ≤ 0.5 × 109/mm3 (p = 0.014), fever (p = 0.039), and acute myeloid leukemia (p = 0.002). We also confirmed that the mortality in the third pandemic wave was significantly lower than in the second wave (p = 0.002). Although vaccination seemed to be a risk-mitigating factor (58.8% [10/17] of those who died from COVID-19 were not vaccinated), no statistically important correlation was found (p = 0.690).

Conclusion: This survey confirmed that the COVID-19 mortality rate was higher in patients with HM (19.9% [31/156]) than in the population. ANC, severity of COVID-19, accession of bacterial infection, hospital stay, fever, and acute myeloid leukemia were the factors that increased mortality in HM patients.

背景:由于免疫缺陷和免疫抑制治疗,血液恶性肿瘤(HM)患者被认为具有发展为包括COVID-19在内的严重和危及生命的感染的高风险。尽管COVID大流行在全球蔓延,但发病率和死亡率数据因国家而异。更准确地识别危险因素将有助于改善HM患者的临床管理。目的:本研究旨在确定拉脱维亚里加东大学医院(REUH) HM和COVID-19患者的真实数据-死亡率、临床结果和影响死亡率的危险因素。材料和方法:在这项回顾性非介入性队列研究中,我们纳入了2020年12月1日至2023年3月31日期间在REUH治疗的持续HM和实验室确诊的COVID-19的成年患者。所有数据采用描述性统计、二元logistic回归、单变量Cox回归模型等方法进行分析。结果:我们登记了156例11种不同HMs的患者。多发性骨髓瘤、非霍奇金淋巴瘤和急性髓系白血病是最常见的HM。COVID-19死亡率为19.9%(31/156)。增加死亡风险的因素包括:COVID-19严重程度(p < 0.001)、细菌感染的增加(p < 0.001)、住院时间延长(p = 0.037)、绝对中性粒细胞计数(ANC)≤0.5 × 109/mm3 (p = 0.014)、发热(p = 0.039)、急性髓性白血病(p = 0.002)。我们还证实,第三波大流行的死亡率显著低于第二波(p = 0.002)。虽然疫苗接种似乎是一个风险缓解因素(58.8%[10/17]的COVID-19死亡患者未接种疫苗),但没有发现统计学上重要的相关性(p = 0.690)。结论:本次调查证实,HM患者的COVID-19死亡率(19.9%[31/156])高于人群。ANC、COVID-19的严重程度、细菌感染的增加、住院时间、发烧和急性髓系白血病是HM患者死亡率增加的因素。
{"title":"FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES.","authors":"A M Rudzite, D Auzina, S Lejniece","doi":"10.15407/exp-oncology.2024.03.260","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.260","url":null,"abstract":"<p><strong>Background: </strong>Patients with hematological malignancies (HM) are considered to have a high risk of developing severe and life-threatening infections including COVID-19 because of immune deficiency and immunosuppressive treatments. Although the COVID pandemic spread worldwide, morbidity and mortality data varied from country to country. A more accurate identification of risk factors would allow the improvement of the clinical management of HM patients.</p><p><strong>Aim: </strong>This study aimed to determine real-life data - the mortality rate, clinical outcomes, and risk factors affecting mortality in patients with HM and COVID-19 at the Riga East University Hospital (REUH) in Latvia.</p><p><strong>Materials and methods: </strong>In this retrospective non-interventional cohort study, we included adult patients treated in REUH with ongoing HM and laboratory- confirmed COVID-19 observed between December 1st, 2020, and March 31st, 2023. All data were analyzed using descriptive statistics, binary logistic regression, univariable Cox regression model, and other methods.</p><p><strong>Results: </strong>We registered 156 patients with 11 different HMs. Multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia were the most common HM. COVID-19 mortality rate was 19.9% (31/156). Factors increasing the risk of death included the severity of COVID-19 (p < 0.001), the accession of bacterial infection (p < 0.001), longer hospital stay (p = 0.037), absolute neutrophil count (ANC) ≤ 0.5 × 109/mm3 (p = 0.014), fever (p = 0.039), and acute myeloid leukemia (p = 0.002). We also confirmed that the mortality in the third pandemic wave was significantly lower than in the second wave (p = 0.002). Although vaccination seemed to be a risk-mitigating factor (58.8% [10/17] of those who died from COVID-19 were not vaccinated), no statistically important correlation was found (p = 0.690).</p><p><strong>Conclusion: </strong>This survey confirmed that the COVID-19 mortality rate was higher in patients with HM (19.9% [31/156]) than in the population. ANC, severity of COVID-19, accession of bacterial infection, hospital stay, fever, and acute myeloid leukemia were the factors that increased mortality in HM patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"260-267"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EFFECT OF ADHESIVE LLC CELL PRETREATMENT BY OXAMATE ON THE SURVIVAL INDEXES AFTER TRANSITION TO DE-ADHESIVE GROWTH. 草氨酸盐预处理粘附性 llc 细胞对过渡到非粘附性生长后存活指标的影响。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.237
Yu Stepanov, D Kolesnik, Yu Yakshibaeva, G Solyanik

Background: The ability to metabolic reprogramming is a distinctive feature of metastatically active tumor cells. A classic example of metabolic reprogramming, characteristic of almost all malignant cells, is aerobic glycolysis. Therefore, inhibition of glycolysis in tumor cells is considered a promising strategy for antitumor therapy.

Aim: To generate Lewis lung carcinoma (LLC) cell subpopulation after pretreatment by a lactate dehydrogenase (LDH) inhibitor - oxamate in adhesive growth conditions, and then to study the metabolism of this subpopulation in the anchorage-independent growth conditions.

Materials and methods: LLC cells were cultured without oxamate or with 17 mM oxamate in the adhesive growth conditions with the following transition to the anchorage-independent growth conditions without oxamate. A distribution of LLC cells by cell cycle phases, apoptosis rate, levels of reactive oxygen species (ROS), E-cadherin, and vimentin were determined by flow cytometry. Glucose consumption and lactate production were determined by spectrophotometry.

Results: 48-h oxamate treatment in adhesive growth conditions resulted in a 30% decrease of the total number of LLC cells compared to the control. In 72 h after the transfer of both oxamate-treated and control cells into the anchorage-independent growth condition without oxamate, the number of viable cells pretreated with oxamate was reduced by 17% (p < 0.05) compared to the control cells. However, the distribution of cells by cell cycle phases did not differ. In cells pre-treated with oxamate, the rate of glucose consumption decreased by 20% (p < 0.05), ROS generation was reduced by 17%, vimentin expression decreased by 10% while the rate of lactate production was the same in oxamate-pretreated and control cells.

Conclusion: The cytostatic effect of oxamate demonstrated in adhesive growth conditions persisted for 72 h in the anchorage-independent growth conditions. The absence of differences in the cell cycle phase distribution and a decrease in the ROS generation may indicate the initial stage of overcoming the cytostatic effect of oxamate after 72 h of culturing LLC cells in anchorage- independent growth conditions.

背景:代谢重编程能力是转移性活性肿瘤细胞的一个显著特征。代谢重编程的一个经典例子是有氧糖酵解,这是几乎所有恶性细胞的特征。因此,抑制肿瘤细胞中的糖酵解被认为是一种很有前途的抗肿瘤治疗策略。目的:采用乳酸脱氢酶(LDH)抑制剂-草酸酯在黏附生长条件下预处理Lewis肺癌(LLC)细胞亚群,并研究该亚群在非锚定生长条件下的代谢情况。材料和方法:将LLC细胞在不含草酸盐和17 mM草酸盐的黏附生长条件下培养,然后过渡到不含草酸盐的非锚定生长条件。流式细胞术检测LLC细胞周期分期、凋亡率、活性氧(ROS)、E-cadherin和vimentin水平的分布。用分光光度法测定葡萄糖消耗量和乳酸产量。结果:在黏附生长条件下,草酸酯处理48小时导致LLC细胞总数比对照组减少30%。将经草酸盐处理的细胞和对照细胞转移到不含草酸盐的非锚定生长条件后72 h,经草酸盐预处理的活细胞数量比对照细胞减少了17% (p < 0.05)。然而,不同细胞周期的细胞分布没有差异。在经草酸预处理的细胞中,葡萄糖消耗率降低了20% (p < 0.05), ROS生成减少了17%,vimentin表达降低了10%,而乳酸生成率与对照细胞相同。结论:在不依赖锚定生长条件下,草酸酯在黏附生长条件下的细胞抑制作用可持续72 h。在不依赖锚定生长条件下培养LLC细胞72 h后,细胞周期期分布没有差异,ROS生成减少,这可能表明LLC细胞在克服草酸酯的细胞抑制作用的初始阶段。
{"title":"EFFECT OF ADHESIVE LLC CELL PRETREATMENT BY OXAMATE ON THE SURVIVAL INDEXES AFTER TRANSITION TO DE-ADHESIVE GROWTH.","authors":"Yu Stepanov, D Kolesnik, Yu Yakshibaeva, G Solyanik","doi":"10.15407/exp-oncology.2024.03.237","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.237","url":null,"abstract":"<p><strong>Background: </strong>The ability to metabolic reprogramming is a distinctive feature of metastatically active tumor cells. A classic example of metabolic reprogramming, characteristic of almost all malignant cells, is aerobic glycolysis. Therefore, inhibition of glycolysis in tumor cells is considered a promising strategy for antitumor therapy.</p><p><strong>Aim: </strong>To generate Lewis lung carcinoma (LLC) cell subpopulation after pretreatment by a lactate dehydrogenase (LDH) inhibitor - oxamate in adhesive growth conditions, and then to study the metabolism of this subpopulation in the anchorage-independent growth conditions.</p><p><strong>Materials and methods: </strong>LLC cells were cultured without oxamate or with 17 mM oxamate in the adhesive growth conditions with the following transition to the anchorage-independent growth conditions without oxamate. A distribution of LLC cells by cell cycle phases, apoptosis rate, levels of reactive oxygen species (ROS), E-cadherin, and vimentin were determined by flow cytometry. Glucose consumption and lactate production were determined by spectrophotometry.</p><p><strong>Results: </strong>48-h oxamate treatment in adhesive growth conditions resulted in a 30% decrease of the total number of LLC cells compared to the control. In 72 h after the transfer of both oxamate-treated and control cells into the anchorage-independent growth condition without oxamate, the number of viable cells pretreated with oxamate was reduced by 17% (p < 0.05) compared to the control cells. However, the distribution of cells by cell cycle phases did not differ. In cells pre-treated with oxamate, the rate of glucose consumption decreased by 20% (p < 0.05), ROS generation was reduced by 17%, vimentin expression decreased by 10% while the rate of lactate production was the same in oxamate-pretreated and control cells.</p><p><strong>Conclusion: </strong>The cytostatic effect of oxamate demonstrated in adhesive growth conditions persisted for 72 h in the anchorage-independent growth conditions. The absence of differences in the cell cycle phase distribution and a decrease in the ROS generation may indicate the initial stage of overcoming the cytostatic effect of oxamate after 72 h of culturing LLC cells in anchorage- independent growth conditions.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"237-243"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
THE INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND LECTIN OF B. SUBTILIS IMV B-7724 ON THE ANTITUMOR IMMUNE RESPONSE OF MICE WITH EHRLICH ADENOCARCINOMA. 动物双歧杆菌和枯草芽孢杆菌b-7724凝集素对埃利希腺癌小鼠抗肿瘤免疫应答的影响。
Pub Date : 2024-12-19 DOI: 10.15407/exp-oncology.2024.03.228
N Fedosova, N Cheremshenko, S Gogol, N Bezdieniezhnykh, V Tikhonov, I Voyeykova, V Konovalenko, V Chekhun

Aim: To investigate the effect of bacteria of the genus Bifidobacterium and the extracellular metabolite of B. subtilis IMV B-7724 on the antitumor immune response of mice with a model tumor.

Materials and methods: The study was conducted on Balb/c mice with transplanted solid Ehrlich adenocarcinoma (ACE). Starting from the 2nd day after the transplantation of tumor cells, the animals of the experimental groups were treated with lectin of B. subtilis IMV B-7724 (s/c, 1 mg/kg of weight), Bifidobacterium animalis (per os, 7 × 105 CFU/mouse) or their combination. The immunological studies were performed on the 21st and 28th days of tumor growth. The functional activity of natural killer cells (NK), cytotoxic T-lymphocytes (CTL), as well as the ability of lymphocytes from the peripheral lymph nodes (PLN) to transform into blast cells under the influence of T- (Con A) and B-cell (LPS) mitogens were determined.

Results: Administration of probiotic components to the mice with ACE led to the activation of innate immune responses, that is, to a significant increase in the cytotoxic activity of NK, especially in the case of their combined use. The NK cytotoxicity index was higher than that in the non-treated ACE-bearing mice and the intact control by 3.7 and 2.1 times, respectively (p < 0.05). Similarly, the highest specific cytotoxic activity of spleen lymphocytes was observed upon the combined use of the microbial preparations: the CTL cytotoxicity index was nearly 2.5-fold higher than in the non-treated ACE-bearing mice. The data on the ability of PLN lymphocytes to transform into blast cells under the influence of Con A and LPS indicated the preservation of the functional activity of lymphocytes in the animals of the experimental groups during ACE growth.

Conclusion: Both B. animalis and lectin of B. subtilis IMV B-7724 have a significant influence on the effectors of the natural and adaptive immunity of mice with ACE. Their combined use was found to be the most effective.

目的:探讨双歧杆菌属细菌和枯草芽孢杆菌胞外代谢物IMV B-7724对模型肿瘤小鼠抗肿瘤免疫应答的影响。材料与方法:采用Balb/c小鼠移植型实体埃利希腺癌(ACE)进行实验研究。从肿瘤细胞移植后第2天开始,实验组动物分别给予枯草芽孢杆菌IMV B-7724凝集素(s/c, 1 mg/kg体重)、动物双歧杆菌凝集素(每只,7 × 105 CFU/只)或两者联合治疗。在肿瘤生长第21天和第28天进行免疫学研究。测定自然杀伤细胞(NK)、细胞毒性T淋巴细胞(CTL)的功能活性,以及外周血淋巴结淋巴细胞(PLN)在T- (Con A)和b细胞(LPS)丝裂原作用下转化成母细胞的能力。结果:对ACE小鼠给予益生菌成分可激活先天免疫反应,即NK细胞毒活性显著增加,特别是在两者联合使用的情况下。NK细胞毒性指数分别比未处理组和对照组高3.7倍和2.1倍(p < 0.05)。同样,联合使用微生物制剂时,脾脏淋巴细胞的特异性细胞毒活性最高:CTL细胞毒指数比未处理的ace小鼠高近2.5倍。Con A和LPS作用下PLN淋巴细胞转化成母细胞的能力数据表明,实验组动物在ACE生长过程中淋巴细胞的功能活性保持不变。结论:动物芽孢杆菌和枯草芽孢杆菌IMV B-7724凝集素对ACE小鼠的自然免疫和适应性免疫效应均有显著影响。他们的联合使用被发现是最有效的。
{"title":"THE INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND LECTIN OF B. SUBTILIS IMV B-7724 ON THE ANTITUMOR IMMUNE RESPONSE OF MICE WITH EHRLICH ADENOCARCINOMA.","authors":"N Fedosova, N Cheremshenko, S Gogol, N Bezdieniezhnykh, V Tikhonov, I Voyeykova, V Konovalenko, V Chekhun","doi":"10.15407/exp-oncology.2024.03.228","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.03.228","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the effect of bacteria of the genus Bifidobacterium and the extracellular metabolite of B. subtilis IMV B-7724 on the antitumor immune response of mice with a model tumor.</p><p><strong>Materials and methods: </strong>The study was conducted on Balb/c mice with transplanted solid Ehrlich adenocarcinoma (ACE). Starting from the 2nd day after the transplantation of tumor cells, the animals of the experimental groups were treated with lectin of B. subtilis IMV B-7724 (s/c, 1 mg/kg of weight), Bifidobacterium animalis (per os, 7 × 105 CFU/mouse) or their combination. The immunological studies were performed on the 21st and 28th days of tumor growth. The functional activity of natural killer cells (NK), cytotoxic T-lymphocytes (CTL), as well as the ability of lymphocytes from the peripheral lymph nodes (PLN) to transform into blast cells under the influence of T- (Con A) and B-cell (LPS) mitogens were determined.</p><p><strong>Results: </strong>Administration of probiotic components to the mice with ACE led to the activation of innate immune responses, that is, to a significant increase in the cytotoxic activity of NK, especially in the case of their combined use. The NK cytotoxicity index was higher than that in the non-treated ACE-bearing mice and the intact control by 3.7 and 2.1 times, respectively (p < 0.05). Similarly, the highest specific cytotoxic activity of spleen lymphocytes was observed upon the combined use of the microbial preparations: the CTL cytotoxicity index was nearly 2.5-fold higher than in the non-treated ACE-bearing mice. The data on the ability of PLN lymphocytes to transform into blast cells under the influence of Con A and LPS indicated the preservation of the functional activity of lymphocytes in the animals of the experimental groups during ACE growth.</p><p><strong>Conclusion: </strong>Both B. animalis and lectin of B. subtilis IMV B-7724 have a significant influence on the effectors of the natural and adaptive immunity of mice with ACE. Their combined use was found to be the most effective.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"46 3","pages":"228-236"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1